Cochrane · systematic review · CD014384
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
Rodolico, A, Siafis, S, Bighelli, I, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 1 · 14.3%Moderate 4 · 57.1%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table ‐ Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life ‐ mean change/endpoint all available scales (combined scales and time points) Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation | no estimate extracted | 6 studies · 719 participants | Moderate Downgraded: risk of bias, imprecision |
Service use ‐ readmission to hospital (combined time points) Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation | RR 1.53 [0.84, 2.81] | 9 studies · 1433 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effect ‐ leaving the study early due to adverse effects ‐ overall tolerability (combined time points) Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation | RR 2.2 [1.39, 3.49] | 10 studies · 1340 participants | Moderate Downgraded: risk of bias |
Functioning ‐ mean endpoint/change all available scales (combined scales and time points) Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation | no estimate extracted | 6 studies · 966 participants | High |
Global state ‐ number of participants with relapse/exacerbations of psychosis (combined time points) Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation | RR 2.16 [1.52, 3.06] | 20 studies · 2481 participants | Low Downgraded: risk of bias, inconsistency |
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation | RR 1.38 [1.05, 1.81] | 12 studies · 1551 participants | Moderate Downgraded: risk of bias, publication bias |
Adverse effects ‐ number of participants with at least 1 adverse effect (combined time points) Summary of findings table ‐ Antipsychotic dose reduction vs dose continuation | RR 1.03 [0.94, 1.12] | 5 studies · 998 participants | Moderate Downgraded: risk of bias |